| 1 |
31222719 | Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. | 2019 Oct |
1 |
| 2 |
29081194 | [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy]. | 2017 Sep 14 |
2 |
| 3 |
26424560 | MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. | 2016 Mar |
2 |
| 4 |
27760757 | Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. | 2016 Dec 29 |
1 |
| 5 |
26035406 | Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value? | 2015 Sep-Oct |
1 |
| 6 |
23335369 | MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. | 2013 Mar 21 |
1 |
| 7 |
23775435 | Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. | 2013 Nov |
1 |
| 8 |
23984080 | Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study. | 2013 |
1 |
| 9 |
22160255 | Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. | 2012 Jun |
1 |
| 10 |
23181121 | Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study. | 2012 Sep |
3 |
| 11 |
21718130 | Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. | 2011 Oct |
1 |
| 12 |
20385988 | Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. | 2010 May 10 |
1 |
| 13 |
19205655 | Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. | 2009 Sep |
1 |
| 14 |
19757311 | Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab. | 2009 Oct |
1 |